Dr. Michiel Betjes, MD
Claim this profileErasmus Medical Center
Studies Antibody Mediated Rejection
1 reported clinical trial
1 drug studied
Area of expertise
1Antibody Mediated Rejection
HLA positive
DSA positive
More about Michiel Betjes, MD
Clinical Trial Related6 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Michiel Betjes, MD has experience with
- Clazakizumab
Breakdown of trials Michiel Betjes, MD has run
Antibody Mediated Rejection
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michiel Betjes, MD specialize in?
Michiel Betjes, MD focuses on Antibody Mediated Rejection and other conditions. In particular, much of their work with Antibody Mediated Rejection has involved HLA positive patients, or patients who are DSA positive.
Is Michiel Betjes, MD currently recruiting for clinical trials?
No, Michiel Betjes, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Michiel Betjes, MD has studied deeply?
Yes, Michiel Betjes, MD has studied treatments such as Clazakizumab.
What is the best way to schedule an appointment with Michiel Betjes, MD?
Apply for one of the trials that Michiel Betjes, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.